An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
The purpose of this Open Label Safety Study is to provide access to and evaluate the safety and tolerability of TPV/r in treatment-experienced patients with advanced HIV-1 infection who have failed at least two PI-containing regimens, and have limited treatment options.
Inclusion Criteria:
Exclusion Criteria:
Hypersensitivity to active ingredients or any of the excipients in tipranavir or ritonavir
Required use of restricted medications.
Female patients of childbearing potential who have a positive pregnancy test at baseline or are breast feeding.
Any medical condition which in the opinion of the investigator would interfere with the patients' ability to participate in or adhere to the requirements of this protocol.
Use of other investigational drugs, within 30 days prior to TPV boosted with ritonavir initiation and for the duration of study participation
Hepatic impairment evidenced by the following baseline laboratory findings:
Luxembourg, Belgium
Campinas - Sp, Brazil
Fortaleza - Ce, Brazil
Porto Alegre - Rs, Brazil
Porto Alegre - Rs, Brazil
Porto Alegre - Rs, Brazil
Rio de Janeiro - Rj, Brazil
Santos - Sp, Brazil
São Paulo - Sp, Brazil
São Paulo - Sp, Brazil
São Paulo - Sp, Brazil
Monteal, Quebec, Canada
Vic (Barcelona), El Salvador
Vizcaya, El Salvador
Aviano - PD, Italy
Cuggiono-MI, Italy
Mestre-VE, Italy
Torrette Di Ancona, Italy
Torrette Di Ancona, Italy
Las Palmas de Gran Canarias, Spain
Navarra, Spain
Plama de Mallorca, Spain